Clinical trials: Normal Population
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Epidermolysis Bullosa Simplex
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma.
- Trial name
- NCT03154333
- Testing
- diacerein 1% ointment
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- Castle Creek Pharmaceuticals, LLC
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Wegeners Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive…
- Trial name
- SPARROW (NCT01446211)
- Testing
- Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- Nordic Pharma SAS
Nail Psoriasis, Nail Damage
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis…
- Conditions
- Nail Psoriasis, Nail Damage, Mycosis
- Trial name
- NCT07029516
- Testing
- Cosmetic patch containing urea applicated daily for 3 months
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- Wooshin Labottach Co., Ltd.
Rheumatoid Arthritis
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already…
- Trial name
- ESCAPE (NCT00713544)
- Testing
- AZD5672, Etanercept
- Where
- 49 sites in Bulgaria, Colombia and 12 more
- Volunteers
- 373 people
- Sponsor
- AstraZeneca
Juvenile Idiopathic Arthritis
Efficacy Study Of Tofacitinib In Pediatric JIA Population
Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
- Trial name
- NCT02592434
- Testing
- CP-690,550 (tofacitinib)
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Psoriasis
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis.
- Trial name
- NCT07719530
- Testing
- The SHR-1139 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis.
- Trial name
- NCT01873677
- Testing
- M518101, Vehicle
- Where
- 31 sites in United States
- Volunteers
- 537 people
- Sponsor
- Maruho North America Inc.
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
- Trial name
- NCT02808312
- Testing
- Cilofexor
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
Maraviroc in Rheumatoid Arthritis
The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.
- Trial name
- NCT00427934
- Testing
- Maraviroc
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Psoriasis
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the…
- Trial name
- NCT00384098
- Testing
- CTA018 cream
- Where
- 16 sites in United States
- Volunteers
- 140 people
- Sponsor
- OPKO Health, Inc.
Rheumatoid Arthritis,Osteoarthritis
A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)
The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines.
- Trial name
- NCT00250445
- Testing
- MK0663, etoricoxib, Comparator: Diclofenac sodium
- Volunteers
- 23,498 people
- Sponsor
- Organon and Co
Xerosis
Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments
Xerosis is one of the most common adverse events in patients treated with new cancer therapies and chemotherapies, such as multi-kinase inhibitors and more specifically, immunological checkpoint inhibitors used in the treatment…
- Trial name
- NCT04181177
- Testing
- Cosmetic product
- Where
- 4 sites in France
- Volunteers
- 29 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis
This is a phase 2 study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02757729
- Testing
- PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Amorepacific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.